Biomarkers /
MDC1
Overview
MDC1 is altered in 2.25% of all cancers with lung adenocarcinoma, cutaneous melanoma, colon adenocarcinoma, endometrial endometrioid adenocarcinoma, and breast invasive ductal carcinoma having the greatest prevalence of alterations [3].
The most common alterations in MDC1 are MDC1 Mutation (1.87%), MDC1 Amplification (0.20%), MDC1 Deletion (0.03%), MDC1 Loss (0.02%), and MDC1 S1148R (1.52%) [3].
Clinical Trials
Significance of MDC1 in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.